Management
Arie Belldegrun, MD, FACS
Vice Chairman, Board of Directors
Chairman, Scientific Advisory Board
Dr. Belldegrun joined Cougar Biotechnology, Inc. in December 2003
as Vice Chairman of the Board of Directors and Chairman of the Scientific
Advisory Board. Dr. Belldegrun is Chief of the Division of Urologic
Oncology and holds the Roy and Carol Doumani Chair in Urologic Oncology
at the David Geffen School of Medicine at the University of California,
Los Angeles (UCLA).
He is also the Founder of Agensys, Inc., a privately held biotechnology
company focused on the development of fully human monoclonal antibodies
to treat solid tumor cancers based on Agensys’ proprietary targets.
Dr. Belldegrun served as founding Chairman of Agensys from 1997-2002
and currently serves on Agensys’ Board of Directors and as a
consultant.
He completed his medical degree at the Hebrew University Hadassah
Medical School in Jerusalem, his post graduate fellowship at the Weizmann
Institute of Science and his residency in Urology at Harvard Medical
School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH
as a research fellow in surgical oncology under Steven A. Rosenberg,
MD, PhD. He is certified by the American Board of Urology and a Fellow
of the American College of Surgeons.
Dr Belldegrun is also on the scientific boards of several biotechnology
and pharmaceutical companies and serves as a reviewer for many medical
journals and granting organizations including the Journal of Urology
and the American Foundation of Urologic Diseases. In addition to holding
several patents, Dr. Belldegrun is the author of several books on
prostate and kidney cancers and has written over 250 scientific publications
with an emphasis on urologic oncology, particularly kidney, prostate
and bladder cancers.
Alan H. Auerbach
Chief Executive Officer/President
Mr. Auerbach joined Cougar Biotechnology, Inc. in May 2003 as Chief
Executive Officer and President. From June 1998 to April 2003, Mr.
Auerbach was Vice President, Senior Research Analyst at Wells Fargo
Securities where he was responsible for research coverage of small
and middle capitalization biotechnology companies, with a focus
on companies in the field of oncology. He had primary responsibility
for technical, scientific and clinical due diligence as well as
selection of biotechnology companies followed by Wells Fargo Securities.
During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey
of analyst performance for stock picking in biotechnology. From
August 1997 to May 1998, Mr. Auerbach was Vice President, Research
Analyst at the Seidler Companies, Inc., where he was responsible
for research coverage of small capitalization biotechnology companies.
Prior to his work as a biotechnology analyst, Mr. Auerbach worked
for Diagnostic Products Corporation, where he designed and implemented
clinical trials in the field of oncology.
Mr. Auerbach received his B.S. in biomedical engineering from Boston
University and his M.S. in biomedical engineering from the University
of Southern California.
Gloria T. Lee, M.D., Ph.D.
Vice President, Clinical Research and Development
Dr. Lee joined Cougar Biotechnology in November 2004 as Vice President of Clinical Research and Development. Prior to Cougar, Dr. Lee was Senior Director, Clinical Development-Oncology at Chiron Corporation since 2003. Prior to Chiron, Dr. Lee was Senior Therapeutic Expert in Oncology at Hoffman La Roche from 1999 to 2003. Dr Lee also served in a variety of clinical development positions at Rhone Poulenc Rorer (now Aventis) from 1994 through 1999 including the position of Associate Director of Medical Affairs where Dr. Lee was responsible for the clinical development of the anticancer drug Taxotere in breast cancer.
Dr. Lee is a board certified medical oncologist and holds an M.D. from The University of Miami School of Medicine and a Ph.D. in molecular biology from Columbia University.
Charles R. Eyler
Vice President of Finance
Mr. Eyler joined Cougar Biotechnology, Inc. in September 2004 as Vice President of Finance. Prior to joining Cougar, Mr. Eyler served as Chief Financial Officer and Chief Operating Officer of Hayes Medical Inc from 1999 to 2004. Prior to Hayes Medical, Mr. Eyler held several financial positions including Director of Finance and Administration at Alphatec Manufacturing, Inc., Division Controller at JBL Scientific, Inc., Division Controller at Surgitek, Inc. and Financial Systems Director at Zimmer, Inc.
Mr. Eyler received his BS from Drexel University and his MBA from Saint Francis College.
|
